CR Sanjiu(000999) 东方证券·2025-02-24 12:52Investment Rating - The report gives a "Buy" rating for the company, with a target price of 56.81 CNY based on a PE valuation of 19 times for 2025 [3][6]. Core Views - The company is positioned as a leading player in the traditional Chinese medicine (TCM) health sector, with both organic growth and external acquisitions driving its long-term growth potential. The CHC (Consumer Health Care) business is expected to maintain steady growth, while the RX (Prescription) business is stabilizing. The company has a strong focus on R&D and has a rich pipeline of projects [3][8]. Financial Performance Summary - The company's revenue increased from 136.4 billion CNY in 2020 to 247.4 billion CNY in 2023, with a CAGR of 19%. The net profit attributable to the parent company rose from 16.0 billion CNY to 28.5 billion CNY during the same period, achieving a CAGR of 21% [23][24]. - For 2024-2026, the projected net profits are 33.7 billion CNY, 38.4 billion CNY, and 43.5 billion CNY, respectively, with corresponding EPS of 2.62 CNY, 2.99 CNY, and 3.39 CNY [3][5]. Business Segments Overview - The CHC business has shown robust growth, with revenues increasing from 75.6 billion CNY in 2019 to 117.1 billion CNY in 2023, reflecting a CAGR of 12%. This segment accounted for approximately 52% of total revenue in the first half of 2024 [41][43]. - The RX business has faced challenges due to policy changes but is focusing on innovation and operational efficiency to adapt [8][41]. Acquisition Strategy - The company has successfully built a TCM health platform through strategic acquisitions, including the recent acquisition of Kunming Pharmaceutical Group, which enhances its market position in cardiovascular products. A planned acquisition of Tian Shi Li is expected to further enrich its product offerings in the cardiovascular sector [8][9][20]. R&D and Innovation - The company has significantly increased its R&D investment from 5.3 billion CNY in 2019 to 8.9 billion CNY in 2023, with a CAGR of 14%. The number of R&D personnel has also grown from 402 to 778 during the same period [32][34]. Shareholder Returns - The company has consistently increased its dividend payouts, with a cash distribution of 15 CNY per 10 shares in 2023, reflecting a commitment to shareholder returns [39][40].